Illustrative image – not actual.Orchid Chemicals & Pharmaceuticals has formed a 50:50 joint venture with Chinese drug maker North China Pharmaceutical Corporation (NCPC), for the manufacture and marketing of injectible antibiotics in China.
NCPC is the largest pharmaceutical group in China.
The new firm, NCPC Orchid Pharmaceuticals Company Ltd, would be set up at a cost of US$ 25 million. Orchid and NCPC would contribute US$ 5 million each as equity, while another US$ 15 million would be raised as debt from Chinese banks, guaranteed by NCPC.
The new company would
initially manufacture and market 6 sterile cephalosporins, according to Orchid’s
managing director, Mr Raghavendra Rao. The joint venture would initially import
non-sterile cephalosporins in bulk form from India and convert it into sterile
injectibles in China.
The firm, with an initial production capacity of 300 tonnes per annum, would be based in Shijiazhuang in north China and is expected to commence initial manufacturing by early 2003.
According to NCPC
chairman, Lu Weichuan, the joint venture would expand the scope of its
operations to look at new drug discovery, bio-technology, fermentation products
and also joint marketing of products of the two parent companies.
